CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
2.430
-0.250 (-9.33%)
At close: Oct 23, 2025, 4:00 PM EDT
2.310
-0.120 (-4.94%)
After-hours: Oct 23, 2025, 7:18 PM EDT
CytoMed Therapeutics Revenue
CytoMed Therapeutics had revenue of 450.69K SGD in the half year ending June 30, 2025, with 58.57% growth. This brings the company's revenue in the last twelve months to 729.88K, up 63.03% year-over-year. In the year 2024, CytoMed Therapeutics had annual revenue of 503.37K, down -0.86%.
Revenue (ttm)
729.88K SGD
Revenue Growth
+63.03%
P/S Ratio
53.96
Revenue / Employee
16,974 SGD
Employees
43
Market Cap
28.04M USD
Revenue Chart
* This company reports financials in SGD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 503.37K | -4.36K | -0.86% |
| Dec 31, 2023 | 507.74K | 143.82K | 39.52% |
| Dec 31, 2022 | 363.91K | 250.07K | 219.67% |
| Dec 31, 2021 | 113.84K | 54.37K | 91.43% |
| Dec 31, 2020 | 59.47K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GDTC News
- 21 days ago - CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 21 days ago - CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - GlobeNewsWire
- 2 months ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 3 months ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 6 months ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 9 months ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 10 months ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga